BOLETÍN INFORMATIVO Nº 3 –MAYO 2023
Estimados colegas del Programa Nacional de Control de Calidad en Bacteriología (PCC-NAC):
En el presente BOLETÍN INFORMATIVO Nº 3 enviamos:
- Novedades CLSI 2023: resumen de las novedades más relevantes publicadas en el documento M100S 33rd Edition del Clinical Laboratory Standards Institute (CLSI): “Performance Standards for Antimicrobial Susceptibility Testing; Thirty third Informational Supplement”. M. Rapoport.?
- The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Karaiskos I, Lagou S, Pontikis K,Rapti V and Poulakou G (2019). Front. Public Health 7:151.doi: 10.3389/fpubh.2019.00151
- Gentamicin Rationale for the EUCAST clinical breakpoints, version 2.0. EUCAST Rationale Document. Abril, 2020.
- Tobramycin Rationale for the EUCAST clinical breakpoints, version 2.0. EUCAST Rationale Document. Abril, 2020.
- Amikacin Rationale for the EUCAST clinical breakpoints, version 2.0. EUCAST Rationale Document. Abril, 2020.
Cariños para todos!
Alejandra y Paola
Servicio Antimicrobianos
LNR/LRR en Resistencia a los Antimicrobianos
INEI-ANLIS. “Dr. Carlos G Malbrán”